Kornimate/medical-research-clean huggingface dataset:
effects of prebiotics on glp-1 in type 2 diabetes

Conditions: Diabetes Type 2

Summary: the aim of the study is to compare the effects of prebiotics versus placebo on blood concentrations of glucagon-like peptide-1 in subjects with diabetes type 2.

we looked at 6 weeks supplementation with a prebiotic fibre mix of inulin and fos. cross over design compared to maltodextrin as placebo. additional outcome measures: blood glucose, insulin, glp-2, ghrelin, pyy and leptin after a standardized mixed meal test. also measured changes in microbiota composition and scfa in feces before and after intervention/placebo periods, and subjective measures of appetite.

Eligibility criteria:
inclusion criteria: * diabetes type 2 * bmi 18,5 - 40 * not medicated with insulin, glp-1 analogues or dpp4 inhibitors * moderate intake of alcohol * not excessive exercise * less than 3 kg weight change the last two months * intake of less than 30 g dietary fiber per day exclusion criteria: * ibd * ibs * coeliac disease * have used antibiotics within the last two months * have used supplements with prebiotics or probiotics the last two months * pregnancy
telerehabilitation as an alternative to face-to-face rehabilitation after total hip arthroplasty

Conditions: Total Hip Arthroplasty (THA)

Summary: the goal of this clinical trial is to learn if telerehabilitation in patients who had undergone total hip arthroplasty. the main questions it aims to answer are: * does telerehabilitation improve the functional level of the participants? * does telerehabilitation improve the locomotor performance of the participants? researchers will compare telerehabilitation to face to face rehabilitation (traditional rehabilitation programme) to see if telerehabilitation works in total hip arthroplasty recovery. participants will: * attend physiotherapy and rehabilitation sessions supervised by a physiotherapist 2 days a week for 8 weeks. * participate in assessments (before surgery and at 6 weeks and 12 weeks after surgery).


Eligibility criteria:
inclusion criteria: * having hip arthroplasty surgery * to be able to understand verbal and written information * no cognitive impairment * to be able to speak and understand turkish exclusion criteria: * having a neurological disease * having a psychiatric disorder * visual or hearing loss that cannot be corrected with any assistive device

Keywords: total hip arthroplasty telerehabilitation
advanced therapy registry of ibd patients

Conditions: Crohn Disease; Ulcerative Colitis; Pouchitis

Summary: the study is aim to detect common microbial profiles and metabolic pathways throughout ibd diagnosis and treatment with biological therapy.

the study is aim to detect common microbial profiles and metabolic pathways in patients belonging to the following groups: 1. therapy naïve newly diagnosed crohn's disease (cd), ulcerative colitis (uc) and pouchitis patients. studying this group of patients will enable the detection of microbial profiles associated with disease onset. 2. patients planned to commence biological therapy (with or without ibd). studying this group of patients will enable the detection of microbial profiles associated with response to biological therapy. 3. ibd patients in complete remission (treated or untreated with biologics). following this group of patients will enable the detection of microbial profiles associated with disease exacerbation. methods: study design: a prospective cohort study. setting: the investigators will prospectively collect clinical, behavioral and environmental data of patients participating in the study. data will be collected according to a uniform standardized protocol specifically adapted to the needs of the study and shared between the collaborators. study population: eligible patients, who sign an informed consent form and answer to all the study inclusion criteria. patients will be informed of the study by their treating physician, recruited and followed throughout the follow-up period by study coordinators. sample size: sample size was estimated according to clinical capabilities of the researcher. we aim to collect data from a total of 1000 patients. schedule: data will be collected between the years 2019-2024. study plan: patient and disease characteristics at baseline, demographic characteristics, medical history and specifically ibd phenotype, severity, extent and location, disease duration, previous medicinal treatment will be documented. baseline and follow-up study visits which will include biological sample collection and questionnaires. patients will be asked to complete questionnaires to account for their lifestyle, sleep, quality of life and disease related symptoms and outcomes. physician global assessment (pga), disease severity using clinical scores (hbi and sccai scores for cd and uc patients) and biochemical data (crp, fecal calprotectin) will be documented.

Eligibility criteria:
inclusion criteria: patients who belong to one of the following sub-groups: 1. newly diagnosed (\<1 years), therapy naïve ibd and pouchitis patients 2. ibd patients in complete remission (treated or untreated with biologics) 3. patients (with and without ibd) scheduled to commence a biological therapy exclusion criteria: 1. age≤18 years 2. inability to sign an informed consent 3. abdominal surgery during the previous 3 months 4. systemic antibiotic therapy in the previous 4 weeks 5. severe systemic disease such as kidney, liver, neurologic, cardio-vascular disease 6. primary sclerosing cholangitis 7. pregnancy at recruitment 8. cancer within the previous 5 years excluding local nmsc
prehospital prediction of the risk of intracranial hemorrhagic injury in the elderly patient with a fall

Conditions: Intracranial Hemorrhages; Head Trauma

Summary: monocentric study at toulouse university hospital. a questionnaire collecting the elements of the study is made available to regulating physicians. the regulating doctor will take charge of the call according to the service's protocol, filling in the regulation form on the appli-samu software. a callback at d7 for patients not transferred and/or not scanned will be carried out by a clinical research associate to gather information on the neurological evolution. if, during this telephone interview, the neurological evolution is not good (gos-e score \< 7), an investigating physician will call back the patient or his trusted person/family/legal representative in order to carry out a medical assessment and propose appropriate management if necessary. patients who have undergone brain imaging will not be recontacted, as it has now been established that normal brain imaging performed on an emergency basis eliminates the risk of delayed cerebral hemorrhagic lesions, even in patients on anticoagulants.

monocentric study at toulouse university hospital. a questionnaire collecting the elements of the study is made available to regulating physicians. all callers (≥ 65 years of age) contacting center 15 for head trauma following a fall from a height are eligible. the regulating doctor will take charge of the call according to the service's protocol, filling in the regulation form on the appli-samu software. he will complete the questionnaire at a later stage, once the patient has been taken into care. a callback at d7 for patients not transferred and/or not scanned will be carried out by a clinical research associate to gather information on the neurological evolution. if, during this telephone interview, the neurological evolution is not good (gos-e score \< 7), an investigating physician will call back the patient or his trusted person/family/legal representative in order to carry out a medical assessment and propose appropriate management if necessary. patients who have undergone brain imaging will not be recontacted, as it has now been established that normal brain imaging performed on an emergency basis eliminates the risk of delayed cerebral hemorrhagic lesions, even in patients on anticoagulants. the medical records of these patients will be consulted by the clinical research team to collect the information required for the study.

Eligibility criteria:
inclusion criteria: * patient ≥ 65 years old * call to the samu/centre 15 following a fall from a height (bed, chair, standing) * proven or suspected head trauma exclusion criteria: * high fall kinetics (greater than 1 m or 5 steps, pedestrian knocked down)
evaluation of efficacy and safety of insulin glargine injected by needle-free jet syringe

Conditions: Diabetes Mellitus, Type 2

Summary: using cgms to compare the blood sugar improvement and patient sensibility of insulin glargine injected with needle-free jet injector and conventional insulin pen

compared with conventional pen, needle-free jet injection of insulin has faster flow rate and larger area of local subcutaneous absorption. the aim of this study was to investigate the effects of subcutaneous insulin glargine injection with needle-free jet injection and conventional pen on blood glucose profile of cgms and safety in type 2 diabetic patients.

Eligibility criteria:
inclusion criteria: * volunteer to participate and be able to sign informed consent prior to the trial. * patients with type 2 diabetes, aged 18-65 years old, meeting who1999 diagnostic criteria, have not used any hypoglycemic drugs. the dosage of insulin glargine (12-18 units) combined with oral medicationis, stable for more than 2 months. * no acute complications such as diabetic ketoacidosis, diabetic hyperosmolar syndrome, etc. * subjects are able and willing to monitor peripheral blood sugar and regularity of diet and exercise. exclusion criteria: * patients with insulin allergy. * impaired liver and kidney function with alt 2.5 times higher than the upper limit of normal value;serum creatinine was 1.3 times higher than the upper limit of normal. * drug abuse and alcohol dependence in the past 5 years. * systemic hormone therapy was used in the last three months. * patients with poor compliance and irregular diet and exercise. * patients with pregnancy, lactation or pregnancy intention. * any other obvious conditions or associated diseases determined by the researcher: such as severe cardiopulmonary diseases, endocrine diseases, neurological diseases, tumors and other diseases, other pancreatic diseases, history of mental diseases.

Keywords: needle-free jet injection insulin glargine flash glucose monitoring
systemic inflammation during recanalization of cerebral arterial occlusion

Conditions: Stroke; Systemic Infection

Summary: strokes management, secondary to proximal arterial occlusion, by endovascular thrombectomy (tm) is now well established. the immuno-inflammatory events of reperfusion after tm are discussed. systemic inflammation is a major factor suggested to explain the limited recovery of the ischemic parenchyma. understanding these phenomena is necessary before developing an immunomodulatory strategy.


Eligibility criteria:
group "avc" : inclusion criteria: * adults patient (s) * ischemic stroke by occlusion of a middle cerebral artery (proximal portion m1) * initial diagnostic mri infusion * tm with complete reperfusion (tici 2b, 2c or 3) * tm performed under local anesthesia +/- anxiolysis, or sedation including propofol * mrs prior to stroke \<2 * barthel index \<90 * included in the hibiscus cohort * patient who was informed and did not object to participating in the study or included through the emergency procedure then collection of his non-objection or that of his trusted person as soon as possible exclusion criteria: * nihss awareness score\> or = 2 * haemorrhagic complication before thrombectomy * pregnant woman * multiple vascular occlusions * occlusions of posterior or anterior cerebral territories other than m1 * protected major * tm performed under general anesthesia * other vital failure than neurological failure group "control" : inclusion criteria: * adults patient (s) * mrs \<2 * barthel index \<90 * requiring diagnostic arteriography for routine check-up of a cerebrovascular malformation * patient who was informed and did not object to participating in the study exclusion criteria: * nihss awareness score\> or = 2 * pregnant woman * protected major * exam performed under general anesthesia
pharmacokinetics of dipyridamole administered as aggrenox® (dipyridamole extended release plus aspirin) capsule versus dipyridamole immediate release plus aspirin following alteration of stomach ph

Conditions: Healthy

Summary: comparison of pharmacokinetics of dipyridamole administered as aggrenox versus dipyridamole administered as the immediate release formulation plus aspirin, under conditions of reduced stomach acidity.


Eligibility criteria:
inclusion criteria: * healthy subjects as determined by results of screening * signed written informed consent in accordance with good clinical practice (gcp) and local legislation * age 40 - 65 years, inclusive, at time of visit 1 * stomach ph \> 4.0 on three consecutive measurements separated by at least five minutes, measured at visits 3b and 5b prior to dosing with aggrenox or dipyridamole-aspirin (dp-asa) exclusion criteria: * any findings of the medical examination (including blood pressure, pulse rate and ecg) deviating from normal and considered by the investigator to be of clinical relevance * gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders considered by the investigator to be of clinical relevance * history of gastro-intestinal ulcer, perforation or bleeding * surgery of the gastro-intestinal tract (except appendectomy) * diseases of the central nervous system (such as epilepsy), neurological disorders, or psychiatric disorders * chronic or relevant acute infections. screening tests will be performed for hiv, hepatitis b, and hepatitis c * history of hypersensitivity to aggrenox or any of the components or excipients * intake of drugs with a long dominant half-life (\>24 hours) 1 month or less prior to visit 1 * use of any drugs which might influence the results of the trial ten days or less prior to visit 1 * participation in another trial with an investigational drug 1 month or less prior to visit 1 * known alcohol abuse * known drug abuse (a drug screening test will be performed at visits 1, 3, and 5) * blood donation 1 month or less prior to visit 1 * excessive physical activities five days or less prior to visit 1 * history of hemorrhagic diathesis * history of bronchial asthma * any laboratory value outside the reference range, considered by the investigator to be of clinical relevance for female subjects: * nursing * pregnancy * positive pregnancy test * no adequate contraception (adequate contraception includes sterilization, intrauterine device, or oral contraceptives) * inability to maintain adequate contraception during the whole study period
contingency management for problematic behavior reduction in the community

Conditions: Schizophrenia; Bipolar Disorder; Anosognosia

Summary: this study aims to determine the feasibility and effectiveness of implementing a contingency management program in a small group of mentally ill, unhoused individuals with schizophrenia or bipolar disorder and anosognosia (a lack of insight into their mental health) in the city of tulsa. the primary objective of the study is to decrease disruptive or problematic behaviors (e.g. interactions with police, emergency services, hospitals, shelter staff, 911 calls) by unhoused individuals in the community through monetary incentives. up to 15 participants will meet weekly for 30 minutes with their case manager to discuss progress on life goals ($10) and for having seven days with no disruptive behaviors (or "trouble-free days") per week at each visit, they will receive an additional baseline payment of $20, increasing with continued success in subsequent weeks by $1 per week.

this study aims to determine the feasibility and effectiveness of implementing a contingency management program in a small group of mentally ill, unhoused individuals with schizophrenia or bipolar disorder and anosognosia (a lack of insight into their mental health) in the city of tulsa. tulsa's unhoused population grew nearly 7% last year to the highest numbers since the beginning of the covid-19 pandemic according to housing solutions data, an organization that oversees many of the city's efforts to address homelessness. the primary objective of the study is to decrease disruptive or problematic behaviors by unhoused individuals in the community through monetary incentives.

Eligibility criteria:
inclusion criteria: 1. age 18-65 years old 2. diagnosis of schizophrenia spectrum, bipolar, or related disorders 3. presence of anosognosia (sumd: minimum combined score of 4 on questions 1) and 2); recent (at least \ 50% of weeks in the 6-month period prior to enrollment) 4. receive case management services through tdc 5. ability to comply with study procedures 6. willingness to participate in contingency management intervention exclusion criteria: 1. inability to provide informed consent 2. unstable medical conditions that would interfere with participation 3. cognitive impairment that would interfere with participation in the study 4. history of severe aggression or violent behavior posing a risk to study staff or other participants 5. active suicidal ideation or a history of suicide attempts within the past 12 months
aztreonam for inhalation solution (azli) for the treatment of exacerbations of cystic fibrosis

Conditions: Cystic Fibrosis; Infection; Pseudomonas

Summary: this study evaluates the role of azli in the treatment of acute pulmonary exacerbations of cf. for consecutive exacerbations patients will receive azli + iv colistin, or two iv anti-pseudomonals.

azli, marketed as cayston, is an inhaled beta-lactam antibiotic. it has a license for the chronic suppression of pseudomonas aeruginosa (pa). current standard practice dictates the use of two iv antipseudomonal antibiotics for the treatment of acute pulmonary exacerbations. the increasing survival, and hence population, in cf means that newer antimicrobial strategies are required in order to manage antimicrobial resistance, minimise adverse systemic effects of heavy antimicrobial exposure and also make effective use of resources. inhaled antibiotics are commonly used in the chronic suppression of pa yet their use has not been thoroughly investigated in acute pulmonary exacerbation. inhaled antibiotics deliver their drugs directly to the target-site with minimal systemic absorbance, making them an attractive candidate for treatment of acute exacerbations. recently, it has become apparent that the bacterial community is much more complex than initially thought. the microbiome, a term used to describe the polymicrobial community in the lungs, has become apparent due to the use of modern culture-independent methods to detect bacteria. the microbiome changes in composition and structure around the time of exacerbations and in response to treatment, although these changes have not been prospectively characterised. we have designed an open-label randomised, controlled cross-over trial to investigate the clinical effectiveness of of azli in the treatment of acute pulmonary exacerbation, whilst simultaneously comparing the effect inhaled and intravenous antibiotics have on the microbiome.

Eligibility criteria:
inclusion criteria: 1. confirmed diagnosis of cf 2. patients aged 18 - 65 years of age who can give informed consent 3. fev1 \>25% or \<75% predicted (in keeping with cayston® license) 4. admitted to the liverpool heart \& chest hospital with an exacerbation of cf pulmonary disease 5. presence of pa in lower respiratory tract cultures in the 6 months prior exclusion criteria: 1. documented allergy to beta-lactam antibiotics or iv colistin 2. growth of burkholderia cepacia complex (bcc) within 2 years 3. pregnancy 4. previous organ transplant 5. receiving other clinical trial medication 6. already prescribed regular cayston®
cocoa intake and muscle pain sensation

Conditions: Muscle Pain

Summary: this experimental randomized, double-blind, and controlled study included fifteen young, healthy, and pain-free men and 15 age-matched women. it lasted for three visits with at least one-week washout. pain was experimentally induced, twice at each visit, with intramuscular injections of 0.2 ml hypertonic saline (5%), before and after intake of one of the different chocolate-types; white (30% cocoa-content), milk (34% cocoa-content), dark (70% cocoa-content). pain duration, pain area, peak pain, and pressure pain threshold were assessed every fifth minute after each injection, between the time-points 5 to 30 min. prior to inclusion, all participants underwent an examination in a dental chair. this included a clinical examination of the orofacial region according to the diagnostic criteria for temporomandibular disorders (dc/tmd) by a blinded examiner. participants were also examined regarding their psychosocial status prior to inclusion, this included depression, somatization, anxiety, pain catastrophizing and stress.


Eligibility criteria:
inclusion criteria: 1. good general health 2. age between 18-40 years exclusion criteria: 1. any pain-related diagnosis of tmd or of the orofacial region 2. any headaches 3. a diagnosis of systemic muscular or joint diseases (fibromyalgia or rheumatoid arthritis) 4. whiplash-associated disorders 5. neurological disorders 6. psychiatric disorders 7. any allergy to the substances used

Keywords: myalgia experimental pain human temporomandibular disorders cocoa
the implementation of prep2 algorithm into clinical practice

Conditions: Stroke; Rehabilitation

Summary: stroke is a worldwide major cause of disability with great social and economic burdens. the recovery of motor function is crucial for the patient to regain independence and quality of life. identifying early predictors of motor recovery and outcomes is useful for planning personalized rehabilitation programs and increasing their efficiency. however, making predictions using a single clinical assessment is often difficult and a combination of multiple tools is required. in the last decades, were validated two predictive algorithms for upper limb function and independent walking that can be easily implemented into clinical practice with the aim of increasing knowledge on expected outcome after stroke in patients, families and rehabilitation teams. this will be the first single-site randomized control trial that will test the implementation of such tools in a rehabilitation setting in italy.


Eligibility criteria:
inclusion criteria: * diagnosis of stroke; * new upper and/or lower limb weakness. exclusion criteria: * cerebellar or bilateral stroke; * contraindication to tms; * cognitive or communication impairment precluding informed consent; * assisted walking prior to admission; * severe medical conditions.

Keywords: rehabilitation efficiency presto algorithms physical rehabilitation stroke motion kinematics brain activity